AR pathway activity can be quantified by a recently developed and validated method, in which expression of AR target genes is measured and subsequently converted into a pathway activity score (ranging between 0 and 100) using a Bayesian computational model.17, 18 Besides, these AR‐related mechanisms, primary ADT resistance may be caused by activity of other tumor‐driving pathways, for instance induced by ERBB2 gene amplification or other tumor‐driving gene mutations. This evidence concerns the gene ERBB2 and neoplasm.